RESUMO
BACKGROUND: Mepolizumab is a therapy for severe asthma. We have little knowledge of the characteristics of people in the US that discontinue mepolizumab in clinical care. OBJECTIVE: To investigate the real-world efficacy and time to clinical discontinuation of mepolizumab, we evaluated individuals with asthma started on mepolizumab at the Cleveland Clinic. We hypothesized that individuals that discontinue mepolizumab have more severe and uncontrolled asthma at baseline. METHODS: Between 2016 and 2022, patients who started on mepolizumab consented to be assessed over 18 months. At baseline, a questionnaire including demographic and medical history was collected. Laboratory findings such as ACT score, FENO (Fractional Excretion of Nitric Oxide), and spirometry were recorded. At the conclusion of the observation period, the participants were divided into two categories: Group A and Group B. RESULTS: Group B [N = 28] discontinued mepolizumab (p < 0.05) at an average of 5.8 months (SD 4.2 months). Group A [N = 129] stayed on the therapy for at least 1 year. A participant with an ACT score less than 13 has an odds ratio of 6.64 (95% CI, 2.1 - 26.0) of discontinuing mepolizumab therapy. For a male, the odds of discontinuing mepolizumab therapy is 3.39 (95% CI, 1.1-11.2). CONCLUSION: In this real-world study, we find that high eosinophil count may not be adequate in screening which individuals will benefit from mepolizumab. Up to 17% of patients fail therapy within 6 months, with male sex and low ACT score increasing risk of mepolizumab discontinuation at Cleveland Clinic.
RESUMO
RATIONALE: Efforts to reduce nitrogen dioxide (NO2 ) have the potential to reduce the morbidity and mortality related to asthma in children. We analyze the associations of pediatric hospital admission rates for asthma with Environmental Protection Agency (EPA) NO2 parameters at the patient zip code level. METHODS: We identified zip codes that had EPA monitors which monitored NO2 levels located in states with high asthma burden. We used the Healthcare Cost and Utilization Project (HCUP) State Inpatient Database (SID) to identify patients who were <17 years of age with diagnosis codes for asthma. We compared NO2 levels at the zip code level with the number of patients hospitalized for asthma from the HCUP SID database. RESULTS: Data from zip codes in Buffalo, Detroit, Phoenix, and Tucson from 2009 to 2011 demonstrated that the monthly mean NO2 levels predicted pediatric asthma hospital admission rates in six monitored zip codes in these four cities with time series modeling (Buffalo zip code 14206, p = 0.0089; Detroit zip code 48205, p = 0.0179; Phoenix zip code 85006, p = 0.0433; Phoenix zip code 85009, p = 0.0007; Phoenix zip code 85015, p = 0.0036; Tucson zip code 85711, p = 0.0004). CONCLUSION: Pediatric admissions to the hospital for asthma exacerbations mirror the cyclic and seasonal pattern of NO2 levels in the cities of Detroit, Buffalo, Phoenix, and Tucson. While traffic density may be higher in cities with periodicity of NO2 and asthma exacerbations, other factors could be contributing to high NO2 levels.
